During the last session, Cue Biopharma Inc (NASDAQ:CUE)’s traded shares were 0.39 million, with the beta value of the company hitting 1.67. At the end of the trading day, the stock’s price was $1.49, reflecting an intraday gain of 7.19% or $0.1. The 52-week high for the CUE share is $2.88, that puts it down -93.29 from that peak though still a striking 69.8% gain since the share price plummeted to a 52-week low of $0.45. The company’s market capitalization is $94.40M, and the average intraday trading volume over the past 10 days was 0.32 million shares, and the average trade volume was 500.64K shares over the past three months.
Cue Biopharma Inc (CUE) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. CUE has a Sell rating from 0 analyst(s) out of 1 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 1 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.14.
Cue Biopharma Inc (NASDAQ:CUE) trade information
Cue Biopharma Inc (CUE) registered a 7.19% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 7.19% in intraday trading to $1.49, hitting a weekly high. The stock’s 5-day price performance is 16.41%, and it has moved by 47.52% in 30 days. Based on these gigs, the overall price performance for the year is -47.54%. The short interest in Cue Biopharma Inc (NASDAQ:CUE) is 1.78 million shares and it means that shorts have 1.54 day(s) to cover.
The consensus price target of analysts on Wall Street is $3, which implies an increase of 50.33% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $2 and $4 respectively. As a result, CUE is trading at a discount of -168.46% off the target high and -34.23% off the low.
Cue Biopharma Inc (CUE) estimates and forecasts
Statistics show that Cue Biopharma Inc has outperformed its competitors in share price, compared to the industry in which it operates. Cue Biopharma Inc (CUE) shares have gone up 114.08% during the last six months, with a year-to-date growth rate more than the industry average at 31.53% against 16.50. In the rating firms’ projections, revenue will increase 71.40% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 1.7M as predicted by 5 analyst(s). Meanwhile, a consensus of 3 analyst(s) estimates revenue growth to 1.27M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 1.82M and 1.72M respectively. In this case, analysts expect current quarter sales to shrink by -6.58% and then drop by -26.17% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 10.55%. While earnings are projected to return 33.69% in 2025, the next five years will return 27.96% per annum.
CUE Dividends
Cue Biopharma Inc is due to release its next quarterly earnings in February. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Cue Biopharma Inc (NASDAQ:CUE)’s Major holders
Cue Biopharma Inc insiders own 0.55% of total outstanding shares while institutional holders control 23.59%, with the float percentage being 23.72%. BLEICHROEDER LP is the largest shareholder of the company, while 69.0 institutions own stock in it. As of 2024-06-30, the company held over 2.86 million shares (or 5.7849% of all shares), a total value of $3.55 million in shares.
The next largest institutional holding, with 2.4 million shares, is of SLATE PATH CAPITAL LP’s that is approximately 4.8567% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $2.98 million.
Also, the Mutual Funds coming in first place with the largest holdings of Cue Biopharma Inc (CUE) shares are Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund . Data provided on Sep 30, 2024 indicates that Vanguard Total Stock Market Index Fund owns about 1.35 shares. This amounts to just over 2.13 percent of the company’s overall shares, with a $2.01 million market value. The same data shows that the other fund manager holds slightly less at 597.57, or about 0.94% of the stock, which is worth about $0.89 million.
